2023年第2版NCCN癌因性疲乏诊治指南述评  

Comments on NCCN guidelines for diagnosis and treatment of cancer-related fatigue, version 2.2023

作　　者：生金 潘宏铭[1] Sheng Jin;Pan Hongming(Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院肿瘤内科,浙江杭州310016

出　　处：《实用肿瘤杂志》2023年第5期416-420,共5页Journal of Practical Oncology

摘　　要：疲乏是癌症患者的常见症状,在接受抗肿瘤治疗的患者中几乎普遍存在。然而,癌因性疲乏(cancer-related fatigue,CRF)在临床中往往缺乏充分地诊断评估及治疗随访。为了解决CRF这一重要问题,美国国立综合癌症网(National Comprehensive Cancer Network,NCCN)CRF诊治指南目前已更新至2023年第2版,综合了该领域的现有研究进展和循证证据,为CRF的诊治提供临床实践指导。该指南的总体目标是确保所有出现CRF的癌症患者都能被识别并得到及时有效的治疗。为促进我国CRF的规范化诊治,提高癌症姑息支持治疗水平,本文就2023年第2版NCCN CRF诊治指南内容作一述评。Fatigue is a common symptom in cancer patients and is almost universal in patients receiving antineoplastic therapy.However,cancer-related fatigue(CRF)often lacks adequate diagnostic assessment and treatment follow-up in the clinical setting.To address this important CRF issue,the National Comprehensive Cancer Network(NCCN)guidelines for the diagnosis and treatment of CRF,now updated to the 2nd edition in 2023,provide clinical practice guidance for fatigue management by integrating existing research advances and evidence-based evidence in the field.The overall goal of the guidelines is to ensure that all cancer patients with fatigue are identified and receive timely and effective treatment.In order to promote the standardized diagnosis and treatment of CRF in China and improve the level of palliative supportive care for cancer patients,this article introduces and reviews the contents of the 2nd edition of the 2023 NCCN guidelines for the diagnosis and treatment of CRF.

关 键 词：癌因性疲乏 姑息支持治疗 生活质量 NCCN指南 

分 类 号：R730[医药卫生—肿瘤]